ZMYND8 Antibody

What is ZMYND8 and why is it significant in research contexts?

ZMYND8 (Zinc finger MYND domain-containing protein 8) is a chromatin reader protein that recognizes specific dual histone modifications, including H3K4me1-H3K14ac and H3.1K36me2-H4K16ac marks. It plays crucial roles in both transcriptional activation and repression mechanisms, making it a fascinating epigenetic regulator. ZMYND8 has been implicated in DNA damage response, cancer metastasis suppression, and neuronal differentiation.

The significance of ZMYND8 spans multiple research fields:

• As an epigenetic regulator that reads specific histone modifications to influence gene expression

• In chromatin remodeling through recruitment of the NuRD complex to damaged chromatin for DNA repair

• As both a transcriptional co-repressor (interacting with KDM5D, KDM5C, and EZH2) and co-activator (through P-TEFb complex)

• In cancer biology, where it suppresses breast and prostate cancer invasion and metastasis

• In neurodevelopment, where it promotes neuronal differentiation by regulating MAPT gene expression

Research on ZMYND8 provides insights into fundamental biological processes and potential therapeutic targets for both cancer and neurodevelopmental disorders.

How do I select the appropriate ZMYND8 antibody for my specific experiment?

Selecting the right ZMYND8 antibody requires consideration of several technical factors:

Application compatibility:

• For Western blotting: Choose antibodies validated for WB (typical dilutions 1:200-1:1000)

• For IHC applications: Select antibodies with demonstrated IHC reactivity (dilutions typically 1:50-1:500)

• For immunoprecipitation: Use antibodies specifically validated for IP (typically 0.5-4.0 μg for 1-3 mg of total protein)

Species reactivity:

• Most ZMYND8 antibodies are validated for human samples

• Some cross-react with monkey (Mk) samples as indicated in product specifications

• For mouse studies, specifically check for confirmed mouse reactivity

Antibody format and validation:

• Polyclonal antibodies (like CAB8737, 11633-1-AP) offer higher sensitivity but potentially lower specificity

• Monoclonal antibodies (like EPR16924/ab201452) provide higher consistency between batches

• KO/KD validated antibodies ensure highest specificity for detecting endogenous protein

• Review validation data including Western blots, IHC images, and published applications

Always validate the antibody with appropriate positive controls (MCF-7 or HeLa cells) in your experimental system before proceeding to experimental samples.

What are the recommended positive controls for validating ZMYND8 antibodies?

Based on published data, these controls are recommended for ZMYND8 antibody validation:

For quantitative experiments, include both high-expressing (MCF-7) and lower-expressing cell types to establish a range of detection. The expression pattern to expect is predominantly nuclear localization, with a molecular weight of approximately 132-180 kDa depending on post-translational modifications. In cancer stem cells, higher expression compared to non-stem cancer cells has been reported, making these populations useful for specificity validation .

How do I optimize Western blot protocols for reliable ZMYND8 detection?

Optimizing Western blot for ZMYND8 detection requires specific technical considerations:

Sample preparation:

• Use nuclear extraction buffers as ZMYND8 is primarily nuclear

• Include protease inhibitors to prevent degradation

• Consider sonication or nuclease treatment for complete extraction of chromatin-bound ZMYND8

Gel electrophoresis and transfer:

• Use 6-8% gels for better resolution of ZMYND8's high molecular weight (~132-150 kDa)

• Load 20-30 μg of total protein per lane

• For large proteins like ZMYND8, use wet transfer with longer transfer times or lower voltage

• Consider adding 0.1% SDS to transfer buffer to improve large protein transfer

Antibody incubation conditions:

• Blocking: 5% non-fat dry milk in TBST is effective (as recommended for ab201452)

• Primary antibody dilutions:

  • Cell Signaling #97845: 1:1000

  • Proteintech 11633-1-AP: 1:200-1:1000

• Incubate primary antibody overnight at 4°C for optimal signal

• Secondary antibody: Use appropriate HRP-conjugated secondary (typically 1:1000-1:5000)

Detection and troubleshooting:

• Expected band size: ~132-180 kDa

• If detecting multiple bands, verify specificity using siRNA knockdown validation

• For weak signals, extend exposure time or consider signal enhancement systems

• MCF-7, HeLa, HEK293, and Jurkat cells serve as suitable positive controls

What are the recommended fixation and antigen retrieval methods for ZMYND8 immunohistochemistry?

Based on published protocols, these methods optimize ZMYND8 detection in tissue samples:

Fixation:

• Formalin-fixed paraffin-embedded (FFPE) tissues are compatible with ZMYND8 IHC

• For cell lines, 4% paraformaldehyde fixation for 10-15 minutes is effective

Antigen retrieval:

• Heat-mediated antigen retrieval is critical for optimal detection

• Preferred buffer: Tris/EDTA buffer pH 9.0 (as recommended for ab201452)

• Alternative: Citrate buffer pH 6.0 may also work but might yield lower sensitivity

Protocol recommendations:

• Section thickness: 4-5 μm for optimal antibody penetration

• Blocking: Use serum-free protein block to reduce background

• Antibody dilutions:

  • ab201452: 1:500 dilution

  • Proteintech 11633-1-AP: 1:50-1:500

• Incubation time: Overnight at 4°C or 1-2 hours at room temperature

• Detection: HRP-polymer detection systems work well

• Counterstain: Hematoxylin provides good nuclear contrast to visualize nuclear ZMYND8 staining

Human cerebral cortex, pancreas, and cervix carcinoma tissues show strong nuclear staining and serve as excellent positive controls. Always include a technical negative control using buffer instead of primary antibody .

How can I validate the specificity of my ZMYND8 antibody?

Validating antibody specificity is crucial for reliable experimental results. For ZMYND8 antibodies, implement these approaches:

Genetic validation:

• Knockout (KO) validation: Test the antibody in ZMYND8 knockout cells

  • Some antibodies like CAB8737 are already KO-validated

  • CRISPR/Cas9 can be used to generate ZMYND8 knockout cell lines

• Knockdown validation: Compare signals between control and ZMYND8 siRNA/shRNA-treated samples

  • Signal should decrease proportionally to knockdown efficiency

Cross-validation with multiple antibodies:

• Test multiple antibodies targeting different epitopes of ZMYND8

• Consistent results across different antibodies suggest specificity

• Compare results from antibodies like ab201452 (EPR16924), 11633-1-AP, and CAB8737

Application-specific validation:

• For Western blot: Single band of expected size (~132-180 kDa)

• For IHC/IF: Expected nuclear localization pattern

• For IP: Mass spectrometry confirmation of pulled-down proteins

• For ChIP: Confirmation of binding to known ZMYND8 target genes

Publication record:

• Check if the antibody has been used in peer-reviewed publications

• The Proteintech antibody 11633-1-AP has been cited in multiple publications for WB, IHC, IF, and ChIP applications

How can ZMYND8 antibodies be used to study its dual role in transcriptional regulation?

ZMYND8 exhibits both transcriptional repressive and activating functions that can be investigated using these approaches:

Chromatin immunoprecipitation (ChIP) strategies:

• Perform ZMYND8 ChIP-seq to identify genomic binding sites

• Compare binding profiles with activating (H3K27ac, H3K4me3) and repressive (H3K27me3) histone marks

• Implement sequential ChIP (Re-ChIP) with:

  • First ChIP using ZMYND8 antibody

  • Second ChIP with corepressor proteins (NuRD complex) or coactivator components (P-TEFb complex)

  • This identifies genomic loci where ZMYND8 and its cofactors co-occur

Protein complex analysis:

• Co-immunoprecipitation using ZMYND8 antibodies to pull down associated complexes

• Western blot for known repressive partners (NuRD complex, KDM5C, KDM5D)

• Western blot for activating partners (P-TEFb complex: CDK9, CyclinT1)

• Mass spectrometry analysis of immunoprecipitated complexes can identify novel interactors

Functional genomics approaches:

• Perform ZMYND8 ChIP before and after stimuli that induce transcriptional changes

• Example: ATRA treatment promotes ZMYND8 localization to H3.1K36me2-H4K16ac marks

• Correlate ZMYND8 binding with gene expression changes using RNA-seq

• Identify gene sets where ZMYND8 binding correlates with increased or decreased expression

Domain-specific function analysis:

• Use antibodies targeting different ZMYND8 domains in combination with expression of domain-specific mutants:

  • Y247A/N248A mutant (defective in histone binding)

  • K1007/1034R mutant (defective in other functions)

These approaches allow comprehensive investigation of how ZMYND8 can function as both transcriptional activator and repressor in different genomic and cellular contexts.

How do ZMYND8 antibodies perform in ChIP applications for studying chromatin interactions?

ZMYND8 antibodies are valuable tools for Chromatin Immunoprecipitation studies investigating its role as a chromatin reader:

ChIP-validated antibodies and optimization:

• Proteintech 11633-1-AP has been validated for ChIP applications in published studies

• Standard 1% formaldehyde crosslinking for 10 minutes is generally sufficient

• Aim for 200-500 bp chromatin fragments for optimal resolution

• Typically use 2-5 μg antibody per ChIP reaction

Target genomic regions to investigate:

• ZMYND8 binds to regions with dual histone modifications:

  • H3K4me1-H3K14ac marks

  • H3.1K36me2-H4K16ac marks

• ATRA-responsive genes show ZMYND8 localization

• DNA damage sites recruit ZMYND8

• MAPT gene regulatory regions show ZMYND8 association during neuronal differentiation

ChIP-seq considerations:

• Standard ChIP-seq protocols are compatible with ZMYND8 antibodies

• Data analysis should focus on enrichment at regions with dual histone modifications

• Expected patterns include enrichment at active enhancers, promoters, and DNA damage sites

• Validation approaches should include comparing ChIP-seq profiles before and after ZMYND8 knockdown

A key advantage of ChIP with ZMYND8 antibodies is the ability to determine how this multifunctional protein associates with different genomic regions to either activate or repress transcription, depending on the chromatin and protein context.

What methodologies can be used to study ZMYND8's interaction with the P-TEFb complex?

ZMYND8 interacts with the P-TEFb complex to regulate transcriptional activation. These methodologies effectively investigate this interaction:

Biochemical characterization:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate ZMYND8 using specific antibodies

  • Probe for P-TEFb components (CDK9, CyclinT1) by Western blot

  • Perform reciprocal IP with CDK9 antibodies to detect ZMYND8

  • Include controls (IgG, input)

• Size exclusion chromatography:

  • Fractionate nuclear extracts using glycerol gradient (20-40%)

  • Analyze co-elution of ZMYND8 with P-TEFb components

  • Western blot fractions for ZMYND8, CDK9, CyclinT1

  • Research shows ZMYND8 co-elutes with CDK9 in specific fractions (17-19)

Functional characterization:

• ChIP-seq correlation:

  • Perform ChIP-seq for ZMYND8 and P-TEFb components

  • Identify genomic regions with co-occupancy

  • Correlate binding with active transcription markers (Pol II Ser2P)

• Reporter assays:

  • Use chromosomally-integrated reporter genes

  • Assess impact of ZMYND8 depletion on P-TEFb recruitment

  • Monitor RNA Pol II phosphorylation (Ser2) as a readout of P-TEFb activity

Specificity analysis:

Technical considerations include optimizing nuclear extraction conditions to preserve protein complexes and selecting antibodies that don't interfere with the interaction interface.

How can ZMYND8 antibodies help investigate its role in DNA damage response?

ZMYND8 plays a critical role in DNA damage response by recruiting the NuRD complex to damaged chromatin. These methodologies effectively investigate this function:

Localization at DNA damage sites:

• Immunofluorescence co-localization:

  • Induce DNA damage using ionizing radiation, UV, or chemical agents

  • Perform IF with ZMYND8 antibodies (e.g., ab201452 at 1:500 dilution)

  • Co-stain for DNA damage markers (γH2AX, 53BP1)

  • Use confocal microscopy to visualize co-localization

• Laser microirradiation:

  • Induce localized DNA damage using laser microirradiation

  • Perform fixed-cell IF with ZMYND8 antibodies

  • Quantify recruitment kinetics and intensity at damage sites

Chromatin association during damage:

• Chromatin immunoprecipitation:

  • Perform ZMYND8 ChIP before and after DNA damage induction

  • Analyze enrichment at known damage-responsive genes

  • Compare binding patterns with histone modifications associated with DNA damage

• Sequential ChIP:

  • First ChIP with ZMYND8 antibody followed by second ChIP with:

    • NuRD complex components (CHD4, HDAC1/2)

    • DNA damage repair factors

Protein complex dynamics:

• Co-immunoprecipitation before and after DNA damage to analyze changes in interacting partners

• Focus on interactions with NuRD complex components which are critical for ZMYND8's role in DNA repair

ZMYND8 recognizes acetylated histone H4 and recruits the NuRD complex to damaged chromatin, making the antibody-based detection of these interactions particularly valuable for understanding DNA damage response mechanisms.

What approaches can be used to study ZMYND8 in cancer metastasis inhibition?

ZMYND8 has significant implications in inhibiting cancer metastasis. These approaches effectively investigate this function:

Expression analysis in cancer models:

• Immunohistochemistry applications:

  • Compare ZMYND8 expression between tumor and adjacent normal tissues

  • Correlate expression with clinical parameters (stage, metastasis, survival)

  • Use validated antibodies like ab201452 at 1:500 dilution with Tris/EDTA buffer pH 9.0 antigen retrieval

• Western blot analysis:

  • Compare ZMYND8 protein levels across cancer cell lines with different metastatic potential

  • Correlate with EMT markers (E-cadherin, N-cadherin, vimentin, TWIST1/2, Snail, Slug)

  • Research shows ZMYND8 knockout increases E-cadherin but decreases N-cadherin and other EMT markers

Functional metastasis studies:

• Invasion assays:

  • Use ZMYND8 antibodies to validate knockdown efficiency

  • Monitor changes in invasive capacity following ZMYND8 depletion

  • Studies show ZMYND8 knockdown increases invasiveness of prostate cancer cells

• In vivo metastasis models:

  • Inject ZMYND8-depleted cancer cells and monitor metastatic spread

  • Use ZMYND8 antibodies to confirm knockdown maintenance in vivo

  • Luciferase imaging systems can quantify metastatic burden

Mechanistic investigations:

• ChIP analysis:

  • Identify ZMYND8 binding sites in metastasis-related gene promoters

  • Analyze how ZMYND8 binding correlates with metastasis-suppressor activity

  • ZMYND8 antagonizes expression of metastasis-linked genes

• Histone modification recognition:

  • Study how ZMYND8 recognizes the dual mark H3K4me1-H3K14ac

  • This recognition function is linked to its anti-metastatic properties

ZMYND8 antibodies are particularly valuable in these studies to establish the correlation between ZMYND8 expression levels and metastatic potential in different cancer types.

How can ZMYND8 antibodies be used in cancer stem cell research?

ZMYND8 plays significant roles in cancer stem cell biology, particularly in breast cancer. These approaches leverage ZMYND8 antibodies for cancer stem cell research:

Cancer stem cell identification:

• Flow cytometry applications:

  • ZMYND8 is preferentially expressed in breast cancer stem cells (BCSCs)

  • Use intracellular staining protocols (fixation/permeabilization required)

  • Combine with established CSC markers (CD44+/CD24-, ALDH high, CD49f)

  • Research shows higher ZMYND8 protein expression in BCSCs compared to non-BCSCs

• Immunofluorescence analysis:

  • Co-stain for ZMYND8 and stem cell markers

  • Analyze subcellular localization in stem versus non-stem populations

  • Quantify expression differences using image analysis software

Functional characterization:

• Western blot analysis:

  • Compare ZMYND8 expression between sorted CSC and non-CSC populations

  • Correlate with stemness markers

  • Studies have shown ZMYND8 is selectively expressed in tumor-initiating cells from mammary tumors

• Knockdown/knockout validation:

  • Use ZMYND8 antibodies to confirm depletion efficiency

  • Analyze effects on stem cell populations

  • Research shows ZMYND8 knockout significantly decreases the percentage of ALDH high or CD44+CD24- BCSCs

Domain function analysis:

• Complementation studies:

  • Reintroduce wild-type or mutant ZMYND8 into knockout cells

  • Monitor restoration of stem cell phenotypes

  • Wild-type but not K1007/1034R mutant ZMYND8 rescues ALDH high BCSCs

  • Both wild-type and Y247A/N248A but not K1007/1034R restore CD44+CD24- BCSCs

This research has significant implications for understanding cancer stem cell biology and developing potential therapeutic approaches targeting ZMYND8-dependent pathways in cancer stem cells.